Small molecule inhibitors targeting SMO such as vismodegib and sonidegib have shown therapeutic efficacy in locally advanced and metastatic BCC, with overall response rates of 40–60 percent and complete responses in about 20 percent of patients [13, 14, 15, 16, 17]. This evidence concerns the gene SMO and skin basal cell carcinoma.